KisoJi Biotechnology Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $29.9M

  • Investors
  • 8

KisoJi Biotechnology General Information

Description

Developer of therapeutic antibody discovery technologies and multi-specific biologics designed for oncology and inflammatory disease treatment. The company's platform integrates multi-species transgenic mice to generate diverse single-domain antibodies with artificial intelligence paratope mapping and structural screening tools to identify rare functional candidates against difficult-to-drug targets, enabling the pharmaceutical industry and clinical researchers to access specific, non-toxic, and modular therapeutic agents that utilize immune cell recruitment for patient outcomes in hard-to-treat solid and hematologic cancers.

Contact Information

Formerly Known As
Actium Research
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3576 Aenue Du Parc
  • Suite 4310
  • Montreal, Quebec H2X 2J1
  • Canada
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Technology Systems
Vertical(s)
Corporate Office
  • 3576 Aenue Du Parc
  • Suite 4310
  • Montreal, Quebec H2X 2J1
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KisoJi Biotechnology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 29-Oct-2024 $29.9M Completed Clinical Trials - Phase 1
2. Later Stage VC 13-Jun-2018 Completed Clinical Trials - Phase 1
1. Later Stage VC (Series A1) 10-Oct-2016 $4M $4M Completed Clinical Trials - Phase 1
To view KisoJi Biotechnology’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

KisoJi Biotechnology Patents

KisoJi Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024402016-A1 System and method for mapping molecules into interfaces Pending 13-Dec-2023
EP-4824794-A1 System and method for mapping molecules into interfaces Pending 13-Dec-2023
US-12749558-B2 System and method for mapping molecules into interfaces Active 13-Dec-2023
US-20250201352-A1 System and method for mapping molecules into interfaces Active 13-Dec-2023
WO-2025123146-A1 System and method for mapping molecules into interfaces Inactive 13-Dec-2023 G16B15/20
To view KisoJi Biotechnology’s complete patent history, request access »

KisoJi Biotechnology Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
adMare Bioinnovations Corporation Minority
Investissement Quebec PE/Buyout Minority
Accel-Rx Accelerator/Incubator Minority
BDC Capital Growth/Expansion Minority
Centre for Commercialization of Regenerative Medicine Corporation Minority
You’re viewing 5 of 8 investors. Get the full list »

KisoJi Biotechnology FAQs

  • When was KisoJi Biotechnology founded?

    KisoJi Biotechnology was founded in 2009.

  • Where is KisoJi Biotechnology headquartered?

    KisoJi Biotechnology is headquartered in Montreal, Canada.

  • What industry is KisoJi Biotechnology in?

    KisoJi Biotechnology’s primary industry is Drug Discovery.

  • Is KisoJi Biotechnology a private or public company?

    KisoJi Biotechnology is a Private company.

  • What is KisoJi Biotechnology’s current revenue?

    The current revenue for KisoJi Biotechnology is .

  • How much funding has KisoJi Biotechnology raised over time?

    KisoJi Biotechnology has raised $33.9M.

  • Who are KisoJi Biotechnology’s investors?

    adMare Bioinnovations, Investissement Quebec, Accel-Rx, BDC Capital, and Centre for Commercialization of Regenerative Medicine are 5 of 8 investors who have invested in KisoJi Biotechnology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process